Fig. 4: Oral administration of B. breve lw01 promotes tumour growth in genetic obese mice. | npj Biofilms and Microbiomes

Fig. 4: Oral administration of B. breve lw01 promotes tumour growth in genetic obese mice.

From: Deconjugating taurocholic acid with Bifidobacterium to mitigate obesity-driven cancer progression by restoring CD8+ T-cell infiltration

Fig. 4

A Schematic of the experimental timeline in ob/ob+PBS-treated and ob/ob+B. breve-treated mice (n = 5 mice/group). B Body weight curves and comparison of body weights at the end point. C Wet weights of eWAT and liver and the liver/body weight ratio at the end of the experiment. D, F In vivo bioluminescence imaging at 9 days after the tumour cell injection (D) and the total radiant efficiency of the abdominal region (F). E, G Macroscopic representation (scale bar = 1 cm; the white arrow indicates the tumour region) and volume of the Hepa1-6-luc tumours. H NK cells, T cells, Tc cells, and Th cells among total single live cells in Hepa1-6 tumours. I Proportions of Tc cells and Th cells among the total T-cell population. J DCs, TAMs and their subsets, and MDSCs among the total single live cells in Hepa1-6 tumours. K Proportions of M1 TAMs and M2 TAMs among the total population of TAMs. The data are presented as the means ± SEMs. *P < 0.05, **P < 0.01, and ns not significant. B. breve Bifidobacterium breve, eWAT epididymal white adipose tissue, NK natural killer, Tc cytotoxic CD8+ T cell, Th helper CD4+ T cell, DCs dendritic cells, TAMs tumour-associated macrophages, MDSCs myeloid-derived suppressor cells.

Back to article page